Proto-Oncogene Proteins c-raf
"Proto-Oncogene Proteins c-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitously expressed raf kinase subclass that plays an important role in SIGNAL TRANSDUCTION. The c-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
Descriptor ID |
D019908
|
MeSH Number(s) |
D08.811.913.696.620.682.700.559.842.500 D12.644.360.400.842.500 D12.776.476.400.842.500 D12.776.624.664.700.204.500
|
Concept/Terms |
Proto-Oncogene Proteins c-raf- Proto-Oncogene Proteins c-raf
- Proteins c-raf, Proto-Oncogene
- Proto Oncogene Proteins c raf
- c-raf, Proto-Oncogene Proteins
- Proto-Oncogene Protein c-raf
- Protein c-raf, Proto-Oncogene
- Proto Oncogene Protein c raf
- c-raf, Proto-Oncogene Protein
- c-raf Kinases
- Kinases, c-raf
- c raf Kinases
- Kinase Raf-1
- Kinase Raf 1
- Raf-1, Kinase
- cRaf1 Kinase
- Kinase, cRaf1
- raf-1 Kinase
- Kinase, raf-1
- raf 1 Kinase
- c-raf Proteins
- Proteins, c-raf
- c raf Proteins
- Kinase p74(raf-1)
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-raf".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-raf".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-raf" by people in this website by year, and whether "Proto-Oncogene Proteins c-raf" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2003 | 2 | 1 | 3 |
2008 | 2 | 0 | 2 |
2009 | 3 | 0 | 3 |
2011 | 0 | 2 | 2 |
2012 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-raf" by people in Profiles.
-
Vu HL, Aplin AE. The Yin-Yang of RAF inhibitors. Pigment Cell Melanoma Res. 2012 Mar; 25(2):127-8.
-
Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res. 2011 Dec 9; 109(12):1401-9.
-
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X, Zhao D, Sun Q, Zeng Z, Dress A, Lin MC, Kung HF, Rui H, Liu LZ, Mao F, Jiang BH, Lai L. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011 Apr 1; 17(7):1722-30.
-
Grabocka E, Bar-Sagi D. Raf-1 and squamous cell carcinoma: Rok-ing the boat. Cancer Cell. 2009 Aug 4; 16(2):85-6.
-
Smith J, Bunaciu RP, Reiterer G, Coder D, George T, Asaly M, Yen A. Retinoic acid induces nuclear accumulation of Raf1 during differentiation of HL-60 cells. Exp Cell Res. 2009 Aug 01; 315(13):2241-8.
-
Pinchot SN, Adler JT, Luo Y, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg. 2009 Mar; 197(3):313-9.
-
Dogan T, Harms GS, Hekman M, Karreman C, Oberoi TK, Alnemri ES, Rapp UR, Rajalingam K. X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol. 2008 Dec; 10(12):1447-55.
-
Adler V, Bowne W, Michl J, Sookraj KA, Ikram K, Pestka S, Izotova L, Zenilman M, Friedman FK, Qu Y, Pincus MR. Site-specific phosphorylation of raf in cells containing oncogenic ras-p21 is likely mediated by jun-N-terminal kinase. Ann Clin Lab Sci. 2008; 38(1):47-56.
-
Rakitina TV, Vasilevskaya IA, O'Dwyer PJ. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res. 2003 Dec 15; 63(24):8600-5.
-
Conner SR, Scott G, Aplin AE. Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem. 2003 Sep 5; 278(36):34548-54.